CytRx President and CEO Steven Kriegsman and CMO Dr. Daniel Levitt Discuss Company Advantages and Oncology Clinical Pipeline Attributes in OncLive Interview - MarketWatch (INNO-206) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, August 22, 2011

CytRx President and CEO Steven Kriegsman and CMO Dr. Daniel Levitt Discuss Company Advantages and Oncology Clinical Pipeline Attributes in OncLive Interview - MarketWatch (INNO-206)




Note: in research

"Previous studies have shown INNO-206 efficacy in tumor models of breast, ovarian, small cell lung cancer, renal cell cancer and pancreatic cancers. Additionally, a recently announced study showed that low doses of INNO-206 and doxorubicin combined achieved complete remission in aggressively growing in vivo ovarian cancer tumors. Several other chemotherapy agents have been attached to the linker used for INNO-206, including paclitaxel, camptothecin, cisplatin and methotrexate, and may be incorporated into future clinical development by the Company."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.